{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-009808","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.018961+00:00","generated_at":"2026-05-16T01:50:33.268712+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC","bullets":["48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.","77% of responders achieved deep responses (≥80% tumor shrinkage); median time to response 1.6 months.","Safety profile consistent with known profile of ficerafusp alfa plus pembrolizumab; generally well tolerated.","Company plans to develop loading and every-three-week maintenance regimen pending regulatory alignment.","Median PFS, DoR, and OS not yet estimable; data continue to mature."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-009808","json":"https://secwatch.observer/filing/0001628280-26-009808.json","markdown":"https://secwatch.observer/filing/0001628280-26-009808.md","text":"https://secwatch.observer/filing/0001628280-26-009808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/0001628280-26-009808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/bcax-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:50:33.268712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}